. 2021 Jul 15;11(7):697. doi: 10.3390/life11070697

Table 3.

Factors potentially associated with % AN reduction in women treated with OCPs.

		AN12	p
Age ^b		−0.30 (0.57)	0.593
Family history ^a	Yes	53.92 (9.25)	0.998
Family history ^a	No	53.89 (7.55)	0.998
Disease duration ^b		−1.21 (0.65)	0.067
Irregular menses ^a	Yes	56.53 (6.76)	0.445
Irregular menses ^a	No	46.41 (11.40)	0.445
Worsening in relation to the menstrual cycle ^a	Yes	69.22 (6.72)	0.083
Worsening in relation to the menstrual cycle ^a	No	47.33 (0.083)	0.083
BMI ^b		−0.72 (0.92)	0.433
Smoking habit ^a	Yes	49.76 (8.99)	0.548
Smoking habit ^a	No	56.90 (7.65)	0.548
OCP type ^a	Combined OCP	59.60 (7.06)	0.173
OCP type ^a	Non-combined OCP	42.84 (9.83)	0.173
Concomitant therapy ^a	Oral doxycycline	57.78 (7.50)	0.417
Concomitant therapy ^a	Clindamycin gel	48.08 (9.18)	0.417
Hurley stage ^a	I	59.52 (9.03)	0.620
	II	51.96 (8.63)
	III	41.67 (16.89)
Number of affected areas ^b		−5.46 (5.24)	0.303

AN, total abscess and inflammatory nodule count; AN12, AN count reduction at week 12; BMI, Body Mass Index; OCP, oral contraceptive pills. ^a The Student’s t test for independent samples or the ANOVA test was used to evaluate the association between AN count reduction week 12 (AN12) and categoric variables, data are expressed as a mean (standard deviation). ^b Simple linear regression was performed to evaluate the association between AN12 and continuous variables, the data are expressed as a beta coefficient (standard deviation).